PHOSPLATIN THERAPEUTICS | A NEW GENERATION OF CANCER THERAPIES

Daniel D. Von Hoff, MD, FACP

Dr. Von Hoff is currently Physician in Chief, Distinguished Professor and Director of the Clinical Translational Research Division at TGen (Translational Genomics Research Institute). He is also Chief Scientific Officer for US Oncology Research and Scottsdale Healthcare’s Clinical Research Institute. From 2004 to 2010, Dr. Von Hoff served on President Bush’s National Cancer Advisory Board. Dr. Von Hoff and his colleagues were involved in the clinical development of many of the therapeutic agents now used routinely, including: paclitaxel, docetaxel, gemcitabine, irinotecan, capecitabine, and others.

Daniel D. Karp, MD

Dr. Karp graduated from Harvard College in 1969, and received his medical degree from the Duke University School of Medicine in 1973. He was awarded numerous postgraduate and clinical fellowships, including at the Sidney Farber Cancer Institute in Boston from 1978-80. Dr. Karp’s focus at MD Anderson Cancer Center is on new drug development in the phase I facility, as well as medical graphics and informatics, and cancer chemoprevention.

Dr. Karp is proud to have had a role in the early clinical trials of epirubicin, the taxanes, and the new targeted oral inhibitors of the epidermal and vascular growth factor receptors, as well as in recent studies of the insulin growth factor receptor (IGFr).

Director of Medical Oncology, NYU School of Medicine

Franco M. Muggia, MD

Franco M. Muggia, MD,is the Anne Murnick Cogan and David H. Cogan Professor of Oncology, the director of the division of medical oncology, and the associate director for clinical research at the New York University School of Medicine. He is the director of the Kaplan Comprehensive Cancer Center and of the breast cancer research program, as well as the director of the division of medical oncology at NYU Medical Center.

An internationally recognized expert and innovator in the early clinical development of novel anticancer compounds, Muggia is a strong advocate for, and is actively engaged in, performing correlative laboratory studies using patient-derived samples to assist in elucidating the mechanisms of action of these novel agents and to guide the development of future clinical trials.

CEO, Collaborative medicinal development

J. Kay Noel, PhD

J. Kay Noel has had thirty years of experience in pharmaceutical drug development. She currently serves as Chief Operating Officer of Collaborative Medicinal Development, a privately held drug development group focused on neuro-degenerative diseases. She was previously co-founder and COO of Oncoethix SA, which was sold to Merck in 2014, and before that was co-founder and VP of Business Development of Oncology Therapeutics Network, which was sold to Bristol Myers Squibb. Earlier in her career she was Director of Biologics R&D at Abbott. Dr. Noel holds a PhD in biophysics from the University of Michigan, and completed post-doctoral studies at UCLA under a fellowship from the National Institutes of Health.

Joseph O’Donnell, MD

Dr. O'Donnell graduated from Harvard College in 1969, began his training at Dartmouth Medical School, and finished medical school in 1973, receiving his M.D. from Harvard. Dr. O’Donnell returned to Hanover to do his residency in internal medicine from 1973-76. He specialized in medical oncology and did a fellowship at the National Cancer Institute from 1976-78.

He then became chief of medical oncology at the White River Junction VA Hospital, where he has practiced medicine since 1978. He also served as Associate Director of the Norris Cotton Comprehensive Cancer Center at Dartmouth College. Dr. O’Donnell advises the American Cancer Society as a member of its Blue Ribbon II committee. He also serves the Dartmouth community through his leadership at the C. Everett Koop Institute.

Investment Director, INKef Capital

Lucas A. De Breed, Ph.D.

Dr. De Breed obtained his Ph.D. from University College London, completing his doctoral research in molecular oncology at the London Research Institute of Cancer Research UK, studying the epigenetic regulation of key tumor suppressor genes.

He established the East Coast office of Deallus Consulting in New York, where he conducted clinical and pipeline strategy engagements for biotechnology and pharmaceutical clients. Dr. De Breed holds an M.B.A. from the Stanford University Graduate School of Business.